United States securities and exchange commission logo





                 February 24, 2021

       Jason Meyenburg
       President and Chief Executive Officer
       Gemini Therapeutics, Inc.
       300 One Kendall Square, 3rd Floor
       Cambridge, MA 02139

                                                        Re: Gemini
Therapeutics, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed February 17,
2021
                                                            File No. 333-253175

       Dear Mr. Meyenburg:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

              Please contact Jordan Metoyer at 202-551-6001 and Joe McCann at
202-551-6262 with
       any questions.




                 Sincerely,


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              Laurie Burlingame, Esq.